Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
14 December 2021 - 8:15AM
Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a
clinical-stage company leveraging its innovative asset-centric
business model to discover, develop and ultimately deliver
impactful medicines to patients, today announced that it has been
added to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition
will become effective prior to market open on Monday, December 20,
2021.
The NASDAQ Biotechnology Index contains securities of
NASDAQ-listed companies classified according to the Industry
Classification Benchmark as either Biotechnology or Pharmaceuticals
which also meet other eligibility criteria. The NASDAQ
Biotechnology Index is calculated under a modified
capitalization-weighted methodology. More information about the
Index can be found at
https://indexes.nasdaqomx.com/index/overview/NBI.
About Centessa PharmaceuticalsCentessa
Pharmaceuticals plc aims to bring impactful new medicines to
patients by combining the strengths of an asset-centric model with
the benefits of scale and diversification typical of larger R&D
organizations. The asset-centric model refers to a highly
specialized, singular-focused company that is led by a team of
well-recognized subject matter experts. Centessa’s asset-centric
companies’ programs range from discovery-stage to late-stage
development and include diverse therapeutic areas such as oncology,
hematology, immunology/inflammation, neuroscience, hepatology,
pulmonology and nephrology. For more information, visit
www.centessa.com.
Contacts:
Investors: Jennifer Porcelli,
Head of Investor Relations Centessa Pharmaceuticals
jennifer.porcelli@centessa.com
Media: Dan Budwick, 1AB
dan@1abmedia.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Oct 2023 to Oct 2024